Angina News and Research RSS Feed - Angina News and Research

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests. [More]
FFR guided drug-eluting stenting reduces death compared to medical therapy in stable CAD patients

FFR guided drug-eluting stenting reduces death compared to medical therapy in stable CAD patients

Fractional flow reserve (FFR)-guided drug-eluting stenting reduces death, myocardial infarction or urgent revascularisation, as compared to medical therapy in patients with stable coronary artery disease (CAD), according to the results of the FAME 2 trial presented for the first time today at ESC Congress by principal investigator Dr Bernard De Bruyne (Belgium). [More]
Darapladib drug fails to reduce risk of recurrent major coronary events

Darapladib drug fails to reduce risk of recurrent major coronary events

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent major coronary events, according to a study published by JAMA. [More]
Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy decreases risk of mortality, CV events, strokes in older adults

Antihypertensive therapy reduces the risk of cardiovascular (CV) events, strokes and mortality in hypertensive older adults, according to research presented at ESC Congress 2014 today by Dr Maciej Ostrowski from Poland. [More]
Study suggests that energy drinks can cause heart problems

Study suggests that energy drinks can cause heart problems

Energy drinks can cause heart problems according to research presented at ESC Congress 2014 today by Professor Milou-Daniel Drici from France. [More]
ESC Guidelines on diagnosis and treatment of aortic diseases published in European Heart Journal

ESC Guidelines on diagnosis and treatment of aortic diseases published in European Heart Journal

The first comprehensive ESC Guidelines on aortic diseases are published today. They are presented at ESC Congress 2014 by Task Force Chairpersons Professor Raimund Erbel (Germany) and Professor Victor Aboyans (France). [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). [More]
First Edition: August 19, 2014

First Edition: August 19, 2014

Today's early morning highlights from the major news organizations, including stories about a how a hospital system's data was hacked, involving as many as 4.5 million patients' records. [More]
Researchers compare benefits of bivalirudin and heparin for patients undergoing coronary stenting

Researchers compare benefits of bivalirudin and heparin for patients undergoing coronary stenting

Bivalirudin and heparin are two anticoagulant options for patients undergoing coronary stenting for ischemic heart disease. Bivalirudin, a newer anticoagulant, has been touted as being as effective as generic heparin, but with nearly half the rate of bleeding. [More]
Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Neovasc revenues increase 58% to $4,404,515 in Q2 2014

Neovasc Inc. ("Neovasc" or the "Company") today announced financial results for the three months ended March 31, 2014. All results are reported in Canadian dollars unless otherwise stated. [More]
Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) has announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is “highly warranted” to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery. [More]
Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). [More]
Findings reveal new way to identify non-antibiotic drugs that could help curb bacterial infections

Findings reveal new way to identify non-antibiotic drugs that could help curb bacterial infections

About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever. [More]
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]

Neovasc's common shares to commence trading on TSX

Neovasc Inc. ("Neovasc" or the "Company") today announced that effective at market opening on June 23, 2014, Neovasc's common shares will commence trading on the Toronto Stock Exchange (the "TSX") under the Company's current trading symbol of "NVC". [More]
Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease. [More]
Blood pressure has heterogeneous associations with cardiovascular diseases

Blood pressure has heterogeneous associations with cardiovascular diseases

The associations between blood pressure and cardiovascular disease are variable, reveals a large study that highlights the impact of angina and heart failure. [More]
Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet. [More]